#ESMO19: Lenvatinib (LEN) and Pembrolizumab (PEMBRO) in Advanced Endometrial Cancer
1 Views
administrator
07/17/23
Kathleen Moore, MD, from the University of Oklahoma Stephenson Cancer Center in Oklahoma City, OK, discusses Lenvatinib (LEN) and Pembrolizumab (PEMBRO) in Advanced Endometrial Cancer (EC), which was presented during Proffered Paper 2: Gynecologic Cancers on Sept. 29 during the European Society for Medical Oncology (ESMO) Congress 2019.
-
Category
Show more
Facebook Comments
No comments found